Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

The reason for this study is to see if the study drug LY3484356 alone or in combination with abemaciclib is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

Official Title

A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Abemaciclib to Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

Keywords

Breast Cancer Advanced Breast Cancer Metastatic Breast Cancer Endometrial Cancer Breast Neoplasms Endometrial Neoplasms Abemaciclib Dose Escalation LY3484356 Dose Escalation LY3484356 + Abemaciclib Dose Expansion LY3484356 Dose Expansion LY3484356 + Abemaciclib

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants must have one of the following:
  • Estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer that may have spread to other part(s) of the body and has had up to 3 lines of standard therapy and progression while on endocrine-containing therapy for ≥24 months in the adjuvant setting or ≥6 months in advanced/metastatic setting
  • Endometrioid endometrial cancer (EEC) having progressed on standard of care and must have had prior platinum-containing therapy
  • Participants must be willing to provide adequate archival tissue sample
  • Participants must be willing to use highly effective birth control
  • Participants must have adequate organ function
  • Participants must be able to swallow capsules

You CAN'T join if...

  • Participants must not have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled
  • Participants must not have another serious medical condition
  • Participants must not have cancer of the central nervous system that is not stable
  • Participants must not be pregnant or breastfeeding

Locations

  • University of California, San Francisco not yet accepting patients
    San Francisco California 94115 United States
  • Seattle Cancer Care Alliance not yet accepting patients
    Seattle Washington 98109 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
ID
NCT04188548
Phase
Phase 1
Study Type
Interventional
Last Updated